Teaching case: A man with a progressive gait impairment and visual compromise

Primary progressive multiple sclerosis can present with a wide variety of symptoms. We report a case of a 52-year-old man presenting with visual symptoms and gait impairment in whom a diagnosis of a primary progressive multiple sclerosis was established. Symptomatic treatment with dalfampridine was...

Full description

Autores:
Toro, Jaime
Burbano, Lisseth Estefania
Zamora, Adrián
Jones, Erica
Tipo de recurso:
Article of journal
Fecha de publicación:
2015
Institución:
Universidad El Bosque
Repositorio:
Repositorio U. El Bosque
Idioma:
eng
OAI Identifier:
oai:repositorio.unbosque.edu.co:20.500.12495/5116
Acceso en línea:
http://hdl.handle.net/20.500.12495/5116
https://doi.org/10.1016/j.msard.2015.02.001
Palabra clave:
Dalfampridine
Gait disorders
Primary progresive multiple sclerosis
Rights
openAccess
License
Acceso abierto
id UNBOSQUE2_2f11c9765f44d70285c92c8f3815b302
oai_identifier_str oai:repositorio.unbosque.edu.co:20.500.12495/5116
network_acronym_str UNBOSQUE2
network_name_str Repositorio U. El Bosque
repository_id_str
dc.title.spa.fl_str_mv Teaching case: A man with a progressive gait impairment and visual compromise
dc.title.translated.spa.fl_str_mv Teaching case: A man with a progressive gait impairment and visual compromise
title Teaching case: A man with a progressive gait impairment and visual compromise
spellingShingle Teaching case: A man with a progressive gait impairment and visual compromise
Dalfampridine
Gait disorders
Primary progresive multiple sclerosis
title_short Teaching case: A man with a progressive gait impairment and visual compromise
title_full Teaching case: A man with a progressive gait impairment and visual compromise
title_fullStr Teaching case: A man with a progressive gait impairment and visual compromise
title_full_unstemmed Teaching case: A man with a progressive gait impairment and visual compromise
title_sort Teaching case: A man with a progressive gait impairment and visual compromise
dc.creator.fl_str_mv Toro, Jaime
Burbano, Lisseth Estefania
Zamora, Adrián
Jones, Erica
dc.contributor.author.none.fl_str_mv Toro, Jaime
Burbano, Lisseth Estefania
Zamora, Adrián
Jones, Erica
dc.contributor.orcid.none.fl_str_mv Toro, Jaime [0000-0001-7129-0058]
dc.subject.keywords.spa.fl_str_mv Dalfampridine
Gait disorders
Primary progresive multiple sclerosis
topic Dalfampridine
Gait disorders
Primary progresive multiple sclerosis
description Primary progressive multiple sclerosis can present with a wide variety of symptoms. We report a case of a 52-year-old man presenting with visual symptoms and gait impairment in whom a diagnosis of a primary progressive multiple sclerosis was established. Symptomatic treatment with dalfampridine was started but did not result in a considerable improvement. Gait disorders in multiple sclerosis are common and can have a considerable effect over the patient׳s quality of life. Dalfampridine is the first drug approved for the symptomatic treatment of gait in MS, although only a 40% of patients show an objective response to this medication. Primary progressive multiple sclerosis represents a therapeutic challenge. Currently, there are no disease modifying treatments approved but there are several medications undergoing assessment for this indication. Further research in the underlying pathophysiology of PPMS will help us develope more successful disease-modifying treatments. Meanwhile, a symptomatic approach should be offered in order to improve the patient׳s quality of life.
publishDate 2015
dc.date.issued.none.fl_str_mv 2015
dc.date.accessioned.none.fl_str_mv 2020-11-23T17:37:51Z
dc.date.available.none.fl_str_mv 2020-11-23T17:37:51Z
dc.type.coar.fl_str_mv http://purl.org/coar/resource_type/c_2df8fbb1
dc.type.coarversion.fl_str_mv http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.local.none.fl_str_mv Artículo de revista
dc.type.coar.none.fl_str_mv http://purl.org/coar/resource_type/c_6501
dc.type.driver.none.fl_str_mv info:eu-repo/semantics/article
format http://purl.org/coar/resource_type/c_6501
dc.identifier.issn.none.fl_str_mv 2211-0356
dc.identifier.uri.none.fl_str_mv http://hdl.handle.net/20.500.12495/5116
dc.identifier.doi.none.fl_str_mv https://doi.org/10.1016/j.msard.2015.02.001
dc.identifier.instname.spa.fl_str_mv instname:Universidad El Bosque
dc.identifier.reponame.spa.fl_str_mv reponame:Repositorio Institucional Universidad El Bosque
dc.identifier.repourl.none.fl_str_mv repourl:https://repositorio.unbosque.edu.co
identifier_str_mv 2211-0356
instname:Universidad El Bosque
reponame:Repositorio Institucional Universidad El Bosque
repourl:https://repositorio.unbosque.edu.co
url http://hdl.handle.net/20.500.12495/5116
https://doi.org/10.1016/j.msard.2015.02.001
dc.language.iso.none.fl_str_mv eng
language eng
dc.relation.ispartofseries.spa.fl_str_mv Multiple Sclerosis and Related Disorders, 2211-0356, Vol. 4, No. 2, 2015, p. 176-179
dc.relation.uri.none.fl_str_mv https://www.msard-journal.com/article/S2211-0348(15)00008-5/fulltext
dc.rights.local.spa.fl_str_mv Acceso abierto
dc.rights.accessrights.none.fl_str_mv http://purl.org/coar/access_right/c_abf2
info:eu-repo/semantics/openAccess
Acceso abierto
dc.rights.creativecommons.none.fl_str_mv 2015-03
rights_invalid_str_mv Acceso abierto
http://purl.org/coar/access_right/c_abf2
2015-03
eu_rights_str_mv openAccess
dc.format.mimetype.none.fl_str_mv application/pdf
dc.publisher.spa.fl_str_mv Elsevier
dc.publisher.journal.spa.fl_str_mv Multiple Sclerosis and Related Disorders
institution Universidad El Bosque
bitstream.url.fl_str_mv https://repositorio.unbosque.edu.co/bitstreams/7410905b-6918-4fa1-a0eb-ab098760b8e6/download
https://repositorio.unbosque.edu.co/bitstreams/96acf6b8-e49d-4804-afa2-c624e158368d/download
https://repositorio.unbosque.edu.co/bitstreams/cf5b29e6-3ec5-460f-8ab6-2771898467c2/download
https://repositorio.unbosque.edu.co/bitstreams/44ce2450-658b-40b6-b162-af70f7cef9e1/download
bitstream.checksum.fl_str_mv eb1073d3c8ba79abb0422eb43d83e49f
8a4605be74aa9ea9d79846c1fba20a33
579ceed07471bd6ac8a78083e2cde029
a8f5c5a4cd5f72353123b1cb3e2bdaa7
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
repository.name.fl_str_mv Repositorio Institucional Universidad El Bosque
repository.mail.fl_str_mv bibliotecas@biteca.com
_version_ 1828164448992362496
spelling Toro, JaimeBurbano, Lisseth EstefaniaZamora, AdriánJones, EricaToro, Jaime [0000-0001-7129-0058]2020-11-23T17:37:51Z2020-11-23T17:37:51Z20152211-0356http://hdl.handle.net/20.500.12495/5116https://doi.org/10.1016/j.msard.2015.02.001instname:Universidad El Bosquereponame:Repositorio Institucional Universidad El Bosquerepourl:https://repositorio.unbosque.edu.coapplication/pdfengElsevierMultiple Sclerosis and Related DisordersMultiple Sclerosis and Related Disorders, 2211-0356, Vol. 4, No. 2, 2015, p. 176-179https://www.msard-journal.com/article/S2211-0348(15)00008-5/fulltextTeaching case: A man with a progressive gait impairment and visual compromiseTeaching case: A man with a progressive gait impairment and visual compromiseArtículo de revistahttp://purl.org/coar/resource_type/c_6501http://purl.org/coar/resource_type/c_2df8fbb1info:eu-repo/semantics/articlehttp://purl.org/coar/version/c_970fb48d4fbd8a85DalfampridineGait disordersPrimary progresive multiple sclerosisPrimary progressive multiple sclerosis can present with a wide variety of symptoms. We report a case of a 52-year-old man presenting with visual symptoms and gait impairment in whom a diagnosis of a primary progressive multiple sclerosis was established. Symptomatic treatment with dalfampridine was started but did not result in a considerable improvement. Gait disorders in multiple sclerosis are common and can have a considerable effect over the patient׳s quality of life. Dalfampridine is the first drug approved for the symptomatic treatment of gait in MS, although only a 40% of patients show an objective response to this medication. Primary progressive multiple sclerosis represents a therapeutic challenge. Currently, there are no disease modifying treatments approved but there are several medications undergoing assessment for this indication. Further research in the underlying pathophysiology of PPMS will help us develope more successful disease-modifying treatments. Meanwhile, a symptomatic approach should be offered in order to improve the patient׳s quality of life.Acceso abiertohttp://purl.org/coar/access_right/c_abf2info:eu-repo/semantics/openAccessAcceso abierto2015-03ORIGINALToro_Jaime_2015.pdfToro_Jaime_2015.pdfapplication/pdf614852https://repositorio.unbosque.edu.co/bitstreams/7410905b-6918-4fa1-a0eb-ab098760b8e6/downloadeb1073d3c8ba79abb0422eb43d83e49fMD51LICENSElicense.txtlicense.txttext/plain; charset=utf-81748https://repositorio.unbosque.edu.co/bitstreams/96acf6b8-e49d-4804-afa2-c624e158368d/download8a4605be74aa9ea9d79846c1fba20a33MD52THUMBNAILToro_Jaime_2015.pdf.jpgToro_Jaime_2015.pdf.jpgIM Thumbnailimage/jpeg12927https://repositorio.unbosque.edu.co/bitstreams/cf5b29e6-3ec5-460f-8ab6-2771898467c2/download579ceed07471bd6ac8a78083e2cde029MD53TEXTToro_Jaime_2015.pdf.txtToro_Jaime_2015.pdf.txtExtracted texttext/plain20007https://repositorio.unbosque.edu.co/bitstreams/44ce2450-658b-40b6-b162-af70f7cef9e1/downloada8f5c5a4cd5f72353123b1cb3e2bdaa7MD5420.500.12495/5116oai:repositorio.unbosque.edu.co:20.500.12495/51162024-02-07 01:24:09.102open.accesshttps://repositorio.unbosque.edu.coRepositorio Institucional Universidad El Bosquebibliotecas@biteca.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